GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ChemoMetec AS (FRA:CHY) » Definitions » Net Change in Cash

ChemoMetec AS (FRA:CHY) Net Change in Cash : €4.36 Mil (TTM As of Dec. 2024)


View and export this data going back to 2019. Start your Free Trial

What is ChemoMetec AS Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

ChemoMetec AS's Net Change in Cash for the six months ended in Dec. 2024 was €-4.21 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2024 was €4.36 Mil.

ChemoMetec AS Net Change in Cash Historical Data

The historical data trend for ChemoMetec AS's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ChemoMetec AS Net Change in Cash Chart

ChemoMetec AS Annual Data
Trend Jun15 Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only Premium Member Only -0.17 7.15 7.92 14.45 -2.74

ChemoMetec AS Semi-Annual Data
Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.40 12.04 -11.33 8.57 -4.21

ChemoMetec AS Net Change in Cash Calculation

ChemoMetec AS's Net Change in Cash for the fiscal year that ended in Jun. 2024 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=17.284+-5.828+-14.164+-0.029
=-2.74

ChemoMetec AS's Net Change in Cash for the quarter that ended in Dec. 2024

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=11.802+-5.865+-10.229+0.08
=-4.21

Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was €4.36 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ChemoMetec AS Net Change in Cash Related Terms

Thank you for viewing the detailed overview of ChemoMetec AS's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

ChemoMetec AS Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ChemoMetec AS (FRA:CHY) » Definitions » Net Change in Cash
Comparable Companies
OCSE:EMBLA OCSE:GN OCSE:SMSMED OCSE:VIRO OCSE:AMBU B ABT BSX SYK MDT XTER:SHL EW SZSE:300760 DXCM XAMS:PHIA STE ZBH PODD XSWX:SOON SHSE:688271 TSE:7733
Traded in Other Exchanges
CHEMMc:UK 0DZ0:UK CHEMM:Denmark CHY:Germany
Address
Gydevang 43, Allerod, DNK, 3450
Website
https://www.chemometec.com
ChemoMetec AS specializes in designing, developing, and producing instruments using patented technology in cell counting and evaluation. It is engaged in the manufacturing and marketing of analytical instruments used for quantitative analysis of cells in liquids. Its applications include Cell Analysis and counting of Mammalian Cells, Yeast Cells, and Sperm Cells. It provides platforms for the determination of viability and cell count of yeast, veterinary semen, mammalian cells, and somatic cells as well as image analysis. It has four segments instruments; consumables; services and others, and the majority of its revenue is generated from the Consumable segment.